Context Therapeutics Statistics
Total Valuation
CNTX has a market cap or net worth of $53.29 million. The enterprise value is -$956,249.
Important Dates
The next estimated earnings date is Wednesday, August 5, 2026, after market close.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CNTX has 91.88 million shares outstanding. The number of shares has increased by 21.69% in one year.
| Current Share Class | 91.88M |
| Shares Outstanding | 91.88M |
| Shares Change (YoY) | +21.69% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 1.36% |
| Owned by Institutions (%) | 29.04% |
| Float | 42.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.02 |
| P/TBV Ratio | 1.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.96, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.96 |
| Quick Ratio | 8.34 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -56.19% and return on invested capital (ROIC) is -37.86%.
| Return on Equity (ROE) | -56.19% |
| Return on Assets (ROA) | -35.83% |
| Return on Invested Capital (ROIC) | -37.86% |
| Return on Capital Employed (ROCE) | -83.17% |
| Weighted Average Cost of Capital (WACC) | 13.04% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.68M |
| Employee Count | 15 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.42% in the last 52 weeks. The beta is 1.61, so CNTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.61 |
| 52-Week Price Change | -11.42% |
| 50-Day Moving Average | 1.97 |
| 200-Day Moving Average | 1.78 |
| Relative Strength Index (RSI) | 19.84 |
| Average Volume (20 Days) | 3,609,649 |
Short Selling Information
The latest short interest is 854,672, so 0.93% of the outstanding shares have been sold short.
| Short Interest | 854,672 |
| Short Previous Month | 896,056 |
| Short % of Shares Out | 0.93% |
| Short % of Float | 2.00% |
| Short Ratio (days to cover) | 0.51 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -43.52M |
| Pretax Income | -40.23M |
| Net Income | -40.23M |
| EBITDA | -43.50M |
| EBIT | -43.52M |
| Earnings Per Share (EPS) | -$0.42 |
Full Income StatementBalance Sheet
The company has $54.53 million in cash and $282,424 in debt, giving a net cash position of $54.25 million or $0.59 per share.
| Cash & Cash Equivalents | 54.53M |
| Total Debt | 282,424 |
| Net Cash | 54.25M |
| Net Cash Per Share | $0.59 |
| Equity (Book Value) | 52.20M |
| Book Value Per Share | 0.57 |
| Working Capital | 51.98M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$32.79 million and capital expenditures -$37,258, giving a free cash flow of -$32.82 million.
| Operating Cash Flow | -32.79M |
| Capital Expenditures | -37,258 |
| Depreciation & Amortization | 16,883 |
| Net Borrowing | n/a |
| Free Cash Flow | -32.82M |
| FCF Per Share | -$0.36 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |